Sucampo Pharmaceuticals, Inc.  

(Public, NASDAQ:SCMP)   Watch this stock  
Find more results for SCMP
+0.05 (0.46%)
Jul 21 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.85 - 11.00
52 week 9.30 - 17.55
Open 11.00
Vol / Avg. 0.00/428,344.00
Mkt cap 511.12M
P/E 18.05
Div/yield     -
EPS 0.61
Shares 46.46M
Beta 1.46
Inst. own 58%
Aug 2, 2017
Q2 2017 Sucampo Pharmaceuticals Inc Earnings Release - 9:30AM EDT - Add to calendar
Aug 2, 2017
Q2 2017 Sucampo Pharmaceuticals Inc Earnings Call - 8:30AM EDT - Add to calendar
Jun 8, 2017
Sucampo Pharmaceuticals Inc at Jefferies Healthcare Conference
Jun 1, 2017
Sucampo Pharmaceuticals Inc Annual Shareholders Meeting
May 18, 2017
Sucampo Pharmaceuticals Inc at Bank of America Merrill Lynch Healthcare Conference - Webcast
May 4, 2017
Sucampo Pharmaceuticals Inc at Deutsche Bank Health Care Conference - Webcast
May 3, 2017
Q1 2017 Sucampo Pharmaceuticals Inc Earnings Release
May 3, 2017
Q1 2017 Sucampo Pharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 8.22% 8.04%
Operating margin 19.30% 17.31%
EBITD margin - 47.46%
Return on average assets 3.53% 3.78%
Return on average equity 10.86% 14.58%
Employees 139 -
CDP Score - -


805 King Farm Blvd Ste 550
ROCKVILLE, MD 20850-6162
United States - Map
+1-301-9613400 (Phone)
+1-301-9613440 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product. VTS-270 is an investigational drug under clinical study for the treatment of Niemann-Pick Disease Type C-1, an ultra-orphan, progressive and fatal disease. AMITIZA is a ClC-2 chloride channel activator, which has been approved for three indications that cover distinct patient types: chronic idiopathic constipation, irritable bowel syndrome with constipation, and opioid-induced constipation. RESCULA is a Big Potassium channel activator used to lower intraocular pressure. CPP-1X/sulindac combination product is meant for the treatment of familial adenomatous polyposis (FAP).

Officers and directors

Peter S. Greenleaf Chairman of the Board, Chief Executive Officer
Age: 47
Bio & Compensation  - Reuters
Peter P. Pfreundschuh CPA Chief Financial Officer, Principal Financial Officer
Age: 48
Bio & Compensation  - Reuters
Max Donley Executive Vice President of Human Resources
Age: 46
Bio & Compensation  - Reuters
Thomas J. Knapp Executive Vice President, Chief Legal Officer and Corporate Secretary
Age: 63
Bio & Compensation  - Reuters
Matthias Alder Executive Vice President
Age: 52
Bio & Compensation  - Reuters
Stanley G. Miele Senior Vice President - Sales and Marketing; President of Sucampo Pharma Americas, LLC
Age: 51
Bio & Compensation  - Reuters
Peter A. Kiener Ph.D. Chief Scientific Officer
Age: 63
Bio & Compensation  - Reuters
Alex Driggs Acting General Counsel, Corporate Secretary
Bio & Compensation  - Reuters
Peter Lichtlen M.D., Ph.D. Chief Medical Officer
Age: 47
Bio & Compensation  - Reuters
John H. Johnson Lead Independent Director
Age: 59
Bio & Compensation  - Reuters